Comparative Analysis Of The Results Of Anti-VEGF Therapy In Patients With AMD

H. Vidinova; D. Antonova; L. Voynov

doi:10.14748/bro.v65i2.7825

Comparative Analysis Of The Results Of Anti-VEGF Therapy In Patients With AMD

H. Vidinova, D. Antonova, L. Voynov

Abstract

Intravitreal injections are one of the most common procedures in ophthalmology. It is connected with direct delivery of drugs in the vitreous body. The aim of our survey is to show our comparative analysis of the results in the treatment of AMD patients with Lucentis and Eylea. Material and methods: We enrolled 24 patients with wet AMD, diagnosed and treated in the ophthalmic department of MMA for a period of 2 years. In 7 of the patients we used Lucentis and in the rest 17 Eylea. All patients were examined for VA, OCT central retinal thickness and FA (Topcon 3D OCT – FA +). The patients were treated according to the Treat and extend protocol with period of extension of 2 weeks. Results: Our results point out that patients treated with Lucentis had an increase of the VA with two lines. They had also a reduction of retinal thickness. In RAP patients Lucentis gave better results than other medications. The Eylea treated patients showed also improvement of the VA, which was more significant than in the previous group. The decrease in the CRT was from approximately 400±130 μm to 288±74 μm in the 6-month follow up. Conclusion: Our survey points out that both Lucentis and Eylea are effective in the treatment of AMD, although aflibercept shows slightly better results in terms of VA and CRT. The treatment of this multifactorial disease is complex and has to be individualized in order to meet the specific needs of the patients. We have to adjust the treatment in each case to be maximum effective.

Keywords

AMD, Lucentis, Eylea, intravitreal injections

Full Text

References

Bressler NM, Bressler SB. Preventative ophthalmology. Age-related macular degeneration [re-view] Ophthalmol, 1995;102:1206-11.

Current Population Reports. Population Projections of the United States by Age, Sex, Race, and Hispanic Origin: 1995-2050. United States Bureau of the Census; Washington, DC, 1996, Series P25-1130.

Plgrim M, Lengyel I, Lanziiretti. Subretinal pigment epithelial deposition of drusen components including hydroxyapatite in primary cell culture model. Investigat Ophthalmol Visual Sci, 2017, 58 (2), 708-719.

The Age-Related Eye Disease Study (AREDS): design implications. AREDS report. The Age-Related Eye Disease Study Research Group Control. Clin Trials, 1999;20:573-600.

Paetkau ME, Boyd TAS, Grace M et al. Senile disciform macular degeneration and smoking. Can J Ophthalmol, 1978;13:67-71.

Risk factors for neovascular age-related macular degeneration. The Eye Disease Case-Control Study Group. Arch Ophthalmol, 1992;110:1701-8.

Vingerling JR, Klaver CCW. Hyman LG et al. Senile macular degeneration: a case-control study. Am J Epidemiol, 1983;118:213-27.

Klein R, Klein BEK, Linton KLP et al. The Beaver Dam Eye Study: the relation of age-related maculopathy to smoking. Am J Epidemiol, 1993;137:190-200.

Smith W, Mitchell P, Leeder SR. Smoking and age-related maculopathy. The Blue Mountains Eye Study. Arch Ophthalmol, 1996;114:1518-23.

Seddon JM, Willett WC, Speizer FE et al. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA, 1996;276:1141-6.

Delcourt C, Diaz JL, Ponton-Sanchez A et al. Smoking and age-related macular degeneration. The POLA Study. Pathologies Oculaires Liees a l′Age. Arch Ophthalmol, 1998;116:1031-5.

Vingerling JR, Dielemans I, Bots ML et al. Age-related macular degeneration is associated with atherosclerosis. The Rotterdam Study. Am J Epidemiol, 1995;142:404-9.

Kahn HS, Leibowitz HM, Ganley JP et al. The Framingham Eye Study: II. Association of ophthalmic pathology with single variables previously measured in the Framingham Heart Study. Am J Epidemiol, 1977;106:33-41.

Sperduto RD, Hiller R. Systemic hypertension and age-related maculopathy in the Framingham Study. Arch Ophthalmol, 1986;104:216-9.

Taylor HR, West S, Muñoz B et al. The long-term effects of visible light on the eye. Arch Ophthalmol, 1992;110:99-104.

Cruickshanks KJ, Klein R, Klein BEK. Sunlight and age-related macular degeneration. The Beaver Dam Eye Study. Arch Ophthalmol, 1993;111:514-8.

Seddon JM, Ajani UA, Sperduto RD et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group [published erratum appears in JAMA 1995;273:622] JAMA, 1994;272:1413-20.

West S, Vitale S, Hallfrisch J et al. Are antioxidants or supplements protective for age-related macular degeneration? Arch Ophthalmol, 1994;112:222-7.

Goldberg J, Flowerdew G, Smith E et al. Factors associated with age-related macular degeneration. An analysis of data from the First National Health and Nutrition Examination Survey. Am J Epidemiol, 1988;128:700-10.

Sanders TAB, Haines AP, Wormald R et al. Essential fatty acids, plasma cholesterol, and fat-soluble vitamins in subjects with age-related maculopathy and matched control subjects. Am J Clin Nutr, 1993;57:428-33.

Christen WG, Glynn RJ, Hennekens CH. Antioxidants and age-related eye disease. Current and future perspectives [review] Ann Epidemiol, 1996;6:60-6.

DOI: http://dx.doi.org/10.14748/bro.v65i2.7825